BIOAVAILABILITY
According to a biopharmaceutic expert, the term
bioavailability may be defined as the rate and extent to which the ingredient
is absorbed from the drug product into the body or to the site of action. It is
measured by blood, serum or plasma levels or from urinary excretion data.
There are three
major factors that govern the efficacy of a dosage form, namely :
(a) Onset of
therapeutic activity.
(b) Intensity
of the therapeutic effect.
(c) Duration of
the therapeutic effect.
The above three factors are solely responsible for the
rate of absorption of the drug, the distribution of the drug throughout the
circulatory system and above all the elimination of the active principle from
the body.
Official quality control methods adopted, e.g., disintegration time and
dissolution rate, do not give ample therapeutic equivalence among drug products
belonging to the same class. Moreover, even the products of the same
manufacturer may have varying degree of bioavailability in different batches.
Therefore, it has become quite necessary to introduce comparative
bioavailability studies and skillfully designed fool-proof clinical tests of
therapeutic equivalence as an effective true remedial measure of the ultimate
performance of drug products.
In 1968, fifty-one patients suffered from an epidemic of
anticonvulsant intoxication in Brisbane. A thorough investigation revealed that
the intoxication was caused by altering one of the excipients from calcium
phosphate to lactose in the drug product Phenytoin Capsule without adequate
pre-testing by the manufacturer.
This apparent minor change of excipient was sufficient
enough to bring about an appreciable major change in enhancing the
bioavailability of the active principles to abnormally high levels in the
affected patients.
It has now been established beyond any reasonable doubt
that quality of a drug product cannot simply be ensured by inspection or
analysis, but a control system has to be built into, from the very beginning of
manufac-ture of a drug. Besides effective quality control measures exercised in
every aspects of production including environment, screening of raw materials,
process controls, intermediate shelf-life of finished products the most important
aspect is to assess the bioavailability of the active principle.
Difference in bioavailability, particularly in drugs with
low solubilty, as ascertained by blood level attainment studies, appears to be
caused by a number of formulation variables, namely : particlesize, crystalline
structure, binding or disintegrating agent, excipient etc., on the release
pattern of the drug in its dosage from. For example : the rate of dissolution
of the drug in tablet or a capsule in the gastrointestinal fluids.
Medical scientists mainly rely on the measurement of
bioavailability of a drug as a positive indicator of therapeutic equivalence,
because clinical efficacy for orally administered drugs depends on the degree
of absorption and the presence of the active ingredient in the blood stream.
Technical information based on in vivo standards and specifications are generally incorporated in
vari-ous official compendia. Hence, in order to record a legitimate assessment
of bioavailability, in vivo test is
an absolute necessity and the relative data obtained therefrom should form an
integral part of the standard specifi-cations in the offcial standard.
Any dosage-form can produce adverse drug reactions.
Hence, a regular feed back of relevant informa-tion on such adverse reactions
from the medical practitioners to the appropriate regulatory authorities and
the concerned manufacturers would not only help to intensify better safety
measures but also widen the scope to improve drug-design by meticulous research
scientists all over the world.
The following two
examples convey the implications of adverse-drug reaction. They are :
Example 1 : Aspirin—Increased gastric damage and
subsequent bleeding caused by some aspirin fomulations have been specifically
attributed to the slowly dissolving aspirin particles in the stomach. However,
both effervescent and highly buffered dosage forms (antacid-aspirin-tablet),
which help in maintaining the aspirin in solution, have been found to minimise
gastro-intestinal toxicity.
Example 2 : Chloramphenicol and
Tetracycline—Sparingly
soluble broad-spectrum antibiotics like chloramphenicol and tetracycline
found to damage the gastrointestinal epithelium besides changing the normal
micro-flora in the GI-tract that are required for normal good health.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.